Stock Scorecard
Stock Summary for Arcutis Biotherapeutics Inc (ARQT) - $8.47 as of 4/26/2024 8:54:59 PM EST
Total Score
8 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for ARQT
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for ARQT
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for ARQT
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for ARQT
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for ARQT
Financial Details for ARQT
Company Overview |
|
---|---|
Ticker | ARQT |
Company Name | Arcutis Biotherapeutics Inc |
Country | USA |
Description | Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company is headquartered in Westlake Village, California. |
Sector Name | LIFE SCIENCES |
Industry Name | PHARMACEUTICAL PREPARATIONS |
Most Recent Quarter | 12/31/2023 |
Next Earnings Date | 5/30/2024 |
Stock Price History |
|
Last Day Price | 8.47 |
Last Day Price Updated | 4/26/2024 8:54:59 PM EST |
Last Day Volume | 2,163,082 |
Average Daily Volume | 3,427,723 |
52-Week High | 15.21 |
52-Week Low | 1.76 |
Last Price to 52 Week Low | 381.25% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 79.17 |
Sector PE | 56.64 |
5-Year Average PE | -3.13 |
Free Cash Flow Ratio | 3.59 |
Industry Free Cash Flow Ratio | 12.71 |
Sector Free Cash Flow Ratio | 30.65 |
Current Ratio Most Recent Quarter | 7.08 |
Total Cash Per Share | 2.36 |
Book Value Per Share Most Recent Quarter | 0.92 |
Price to Book Ratio | 13.20 |
Industry Price to Book Ratio | 5.66 |
Sector Price to Book Ratio | 22.15 |
Price to Sales Ratio Twelve Trailing Months | 19.67 |
Industry Price to Sales Ratio Twelve Trailing Months | 5.48 |
Sector Price to Sales Ratio Twelve Trailing Months | 5.17 |
Share Statistics |
|
Total Shares Outstanding | 114,971,000 |
Market Capitalization | 973,804,370 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Dividend Aristocrat? | False |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | 15.83% |
Reported EPS 12 Trailing Months | -3.78 |
Reported EPS Past Year | 0.00 |
Reported EPS Prior Year | -3.92 |
Net Income Twelve Trailing Months | -262,140,000 |
Net Income Past Year | -262,140,000 |
Net Income Prior Year | -311,458,000 |
Quarterly Revenue Growth YOY | 356.80% |
5-Year Revenue Growth | 0.00% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 271,858,000 |
Total Cash Past Year | 271,858,000 |
Total Cash Prior Year | 409,589,000 |
Net Cash Position Most Recent Quarter | 70,059,000 |
Net Cash Position Past Year | 70,059,000 |
Long Term Debt Past Year | 201,799,000 |
Long Term Debt Prior Year | 197,769,000 |
Total Debt Most Recent Quarter | 201,799,000 |
Equity to Debt Ratio Past Year | 0.31 |
Equity to Debt Ratio Most Recent Quarter | 0.31 |
Total Stockholder Equity Past Year | 88,667,000 |
Total Stockholder Equity Prior Year | 209,581,000 |
Total Stockholder Equity Most Recent Quarter | 88,667,000 |
Options |
|
Put/Call Ratio | 0.02 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | -0.25 |
MACD Signal | 0.08 |
20-Day Bollinger Lower Band | 1.02 |
20-Day Bollinger Middle Band | 7.42 |
20-Day Bollinger Upper Band | 13.83 |
Beta | 1.14 |
RSI | 38.65 |
50-Day SMA | 7.00 |
200-Day SMA | 18.34 |
System |
|
Modified | 4/26/2024 6:15:19 PM EST |